IL-29/IFN-lambda 1 Antibody [Biotin]

• Reactivity: Hu
• Applications: WB, ELISA(Det)
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Biotin
• Concentration: LYOPH

IL-29/IFN-lambda 1 Antibody [Biotin] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human IL‑29/IFN‑ lambda 1
  Gly20-Thr200
  Accession # Q8IU54
• Specificity: Detects human IL‑29/IFN‑ lambda 1 in ELISAs and Western blots. In sandwich immunoassays, approximately 100% cross-reactivity with recombinant human (rh) IL-28B is observed, 35% cross-reactivity with rhIL-28A is observed and less than 0.2% cross‑reactivity with rhIFN‑ alpha A, rhIFN-alpha B2, rhIFN‑ alpha G, rhIFN alpha I, and rhIFN-beta 1A is observed. In Western blots, approximately 25% cross-reactivity with rhIL-28A and rhIL‑28B is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: IFNL1
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • ELISA Capture (Matched Antibody Pair) 2-8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.1-0.4 ug/mL
  • ELISA Standard (Matched Pair)
  • Western Blot 0.1 ug/mL
• Application Notes: ELISA Capture: Human IL-29/IFN-lambda 1 Antibody (Catalog # MAB15981)
  ELISA Detection: Human IL-29/IFN-lambda 1 Biotinylated Antibody (Catalog # BAF1598)
  Standard: Recombinant Human IL-29/IFN-lambda 1 (Catalog # 1598-IL)
• Readout System:
  • Streptavidin Native Protein NBP2-29367
  • Streptavidin Native Protein NBP2-29370
  • Streptavidin Native Protein NBP2-29371

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IL-29/IFN-lambda 1 Antibody [Biotin]

• cytokine Zcyto21
• IFNL1
• IFN-lambda 1
• IFN-lambda-1
• IL29
• IL-29
• interferon lambda-1
• interferon, lambda 1
• interleukin 29 (interferon, lambda 1)
• interleukin-29
• ZCYTO21

Background

IL-28A, IL-28B, and IL-29, also named interferon-lambda 2 (IFN-lambda 2), IFN-lambda 3, and IFN-lambda 1, respectively, are class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11-13% aa sequence identity) and the type I IFN family (15-19% aa sequence identity) (1-3). The genes encoding these three cytokines are localized to chromosome 19 and each is composed of multiple exons. The exon organization of these genes is also found in the IL-10 family genes but is distinct from the type I IFNs, which are encoded within a single exon, The expression of IL-28A, B, and IL‑29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and up-regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor  beta (IL-10 R beta ) and a novel IL-28 receptor  alpha (IL-28 R alpha , also known as IFN-lambda R1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation. The phosphorylated STAT1 and STAT2 complex with IFN-regulatory factor 9 (IRF-9) to form the IFN-stimulated regulatory factor 3 (ISGF-3) transcription factor complex that is translocated to the nucleus. ISGF-3 binds to the IFN-stimulated response element (ISRE) present in the regulatory region of the target genes. Human IL-29 cDNA encodes a 200 amino acid (aa) residue precursor protein with a putative 19 aa signal peptide and a 181 aa mature protein, which is a monomer in solution. It shares 67% and 69% aa sequence identity with human IL-28A and IL-28B, respectively.

1. Vilcek, J. (2003) Nature Immunol. 4:8.
2. Sheppard, P. et al. (2003) Nature Immunol. 4:63.
3. Kotenko, S.V. et al. (2003) Nature Immunol. 4:69.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IL-29/IFN-lambda 1 Antibody (BAF1598)(4)

Publications using BAF1598

• V Oke, I Gunnarsson, J Dorschner, S Eketjäll, A Zickert, TB Niewold, E Svenungsso High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus Arthritis Res. Ther., 2019-04-29;21(1):107. 2019-04-29 [PMID: 31036046] (ELISA Detection, Human)
• V Oke, S Brauner, A Larsson, J Gustafsson, A Zickert, I Gunnarsson, E Svenungsso IFN-?1 with Th17 axis cytokines and IFN-? define different subsets in systemic lupus erythematosus (SLE) Arthritis Res. Ther., 2017-06-15;19(1):139. 2017-06-15 [PMID: 28619037] (Human)
• Iva Gunnarsson Interferon (IFN)-? is a potential mediator in lupus nephritis Lupus Sci Med, 2016-11-22;3(1):e000170. 2016-11-22 [PMID: 27933198] (ELISA Development (Detection), Human)
• Yang K, Puel A, Zhang S, Eidenschenk C, Ku CL, Casrouge A, Picard C, von Bernuth H, Senechal B, Plancoulaine S, Al-Hajjar S, Al-Ghonaium A, Marodi L, Davidson D, Speert D, Roifman C, Garty BZ, Ozinsky A, Barrat FJ, Coffman RL, Miller RL, Li X, Lebon P, Rodriguez-Gallego C, Chapel H, Geissmann F, Jouanguy E, Casanova JL Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha/beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses. Immunity, 2005-11-01;23(5):465-78. 2005-11-01 [PMID: 16286015] (ELISA Development, Human)

Bioinformatics

• Gene Symbol: IFNL1
• Uniprot:
  • Q8IU54()